IBI129 / Innovent Biologics - LARVOL DELTA

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Completed

First-in-human • Trial completion • Oncology • Solid Tumor

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=36 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | N=180 ➔ 36

Enrollment change • First-in-human • Oncology • Solid Tumor

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Completed

Trial completion • Solid Tumor

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Two innovative ADCs from Innovent Biologics have been approved for clinical use in China, targeting solid tumors! [Google translation] (163.com) - "Today (March 19), the official website of the Center for Drug Evaluation (CDE) of the China State Food and Drug Administration announced that IBI130 developed by Innovent Biologics has been approved for clinical use and is planned to be developed for unresectable locally advanced or metastatic solid tumors . A few days ago (March 13), IBI129 developed by the company has just been approved for clinical use in China and is planned to be developed for the treatment of advanced malignant solid tumors. According to the official website of Innovent, IBI130 is an antibody drug conjugate (ADC) targeting TROP2 , and IBI129 is an ADC targeting B7-H3."

New trial • Oncology • Solid Tumor

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor